Impact of previous admission to an intensive care unit on stem cell transplantation outcome.

Intensive care unit Prognosis Pronóstico Stem cell transplantation Supervivencia Survival Trasplante de progenitores hematopoyéticos Unidad de cuidados intensivos

Journal

Medicina clinica
ISSN: 1578-8989
Titre abrégé: Med Clin (Barc)
Pays: Spain
ID NLM: 0376377

Informations de publication

Date de publication:
13 11 2020
Historique:
received: 03 09 2019
revised: 20 12 2019
accepted: 09 01 2020
pubmed: 21 6 2020
medline: 15 5 2021
entrez: 21 6 2020
Statut: ppublish

Résumé

The impact of an admission to ICU before stem cell transplantation (SCT) on post-SCT outcome is not well established. We reviewed the medical records of patients who had received a first SCT between 2000 and 2016 in our institution. The outcome of 22 patients who required ICU admission during chemotherapy prior to SCT (ICU group) was compared with 44 matched patients (1:2) who did not need it (NO-ICU group). There were no differences in transplant complications, in time to neutrophil and platelet recovery or in the length of hospital stay during SCT between the ICU and NO-ICU groups. However, microbiologically documented infections were more common in the ICU group (16/20) than in the NO-ICU group (18/39) (p=.027). The 5-yr overall survival probability (CI 95%) was 49% (28-70%) in the ICU vs. 45% (29-61%) in the NO-ICU group (p=.353), while the 5-yr incidence of non-relapse mortality was 32% (14-52%) and 24% (12-38%) (p=.333), respectively. Six patients (27%) in the ICU group and 8 (18%) in the NO-ICU group required admission to the ICU during or after the SCT procedure (p=.293). Twelve (54%) patients in the ICU and 22 (50%) in the NO-ICU group died, the causes of death were similar in both groups. Our results show that admission to the ICU prior to SCT does not have a negative impact on patient outcomes following SCT and should not be considered as an exclusion criterion for SCT.

Identifiants

pubmed: 32561189
pii: S0025-7753(20)30190-1
doi: 10.1016/j.medcli.2020.01.034
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

382-387

Informations de copyright

Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

Auteurs

Edurne Sarrate (E)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Maria-José Jiménez (MJ)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Mireia Morgades (M)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Pilar Marcos (P)

Intensive Care Department, Hospital Universitari Germans Trias I Pujol, Universitat Autónoma de Barcelona, Badalona, Spain.

Pilar Ricart (P)

Intensive Care Department, Hospital Universitari Germans Trias I Pujol, Universitat Autónoma de Barcelona, Badalona, Spain.

Susana Vives (S)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Blanca Xicoy (B)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Anna Torrent (A)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

María-Teresa Misis (MT)

Intensive Care Department, Hospital Universitari Germans Trias I Pujol, Universitat Autónoma de Barcelona, Badalona, Spain.

Maria-Luisa Bordeje (ML)

Intensive Care Department, Hospital Universitari Germans Trias I Pujol, Universitat Autónoma de Barcelona, Badalona, Spain.

Montserrat Batlle (M)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Miriam Moreno (M)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Juan-Manuel Sancho (JM)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Josep-Maria Ribera (JM)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.

Christelle Ferra (C)

Department of Hematology, ICO-Badalona, Hospital Universitari Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain. Electronic address: cferra@iconcologia.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH